Abecma (idecabtagene vicleucel) / BMS, 2seventy bio  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121

Completed
N/A
50
US
Safety and efficacy assessments
Celgene
Multiple Myeloma
10/19
10/19
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available
N/A
US
Nonconforming idecabtagene vicleucel, BB2121
Celgene
Multiple Myeloma
 
 

Download Options